Biological properties of the recombinant influenza A/H1N1pdm09 virus expressing a fragment of the Streptococcus pneumoniae surface protein
- Authors: Desheva Y.A.1,2, Rekstin A.R.1, Mayorova I.V.1, Kopylova N.V.1, Kopteva O.S.1,2, Petrachkova D.S.1, Kudar P.A.1, Kotomina T.S.1, Matushkina A.S.1, Leontieva G.F.1, Kramskaya T.A.1, Isakova-Sivak I.N.1
-
Affiliations:
- Institute of Experimental Medicine
- Saint Petersburg State University
- Issue: Vol 24, No 4 (2024)
- Pages: 41-50
- Section: Original research
- URL: https://journal-vniispk.ru/MAJ/article/view/284821
- DOI: https://doi.org/10.17816/MAJ633390
- ID: 284821
Cite item
Abstract
BACKGROUND: Live influenza vaccine strains may serve as a promising system for the delivery of target antigens to the body because such a vaccine is administered intranasally and stimulates multiple chains of immunity against both the target pathogen and the influenza virus, a serious infection that causes significant socioeconomic damage worldwide each year.
AIM: The study was aimed to evaluate the biological properties of a recombinant live influenza vaccine strain of subtype A/H1N1pdm09 expressing a fragment of the Streptococcus pneumoniae Spr1875 surface protein.
MATERIALS AND METHODS: The A/H1N1pdm09 recombinant live influenza vaccine strain expressing a 69-amino-acid fragment of the S. pneumoniae surface protein Spr1875 as part of a chimeric hemagglutinin molecule was prepared by reverse genetics using an 8-plasmid system. The reproductive activity of the recombinant virus was studied in chicken embryos, whereas immunogenicity and protective efficiency were studied in Balb/C mice.
RESULTS: The recombinant influenza virus strain with hemagglutinin H1-Spr-69 demonstrated active reproduction in chicken embryos and retained the temperature-sensitive phenotypic trait of vaccine viruses. However, its growth in the respiratory tract of mice was limited compared with the original A/H1N1pdm09 vaccine virus. Intranasal administration of the recombinant H1-Spr strain to mice resulted in stimulation of virus-specific serum IgG antibody production comparable to that induced by the classic live influenza A/H1N1pdm09 vaccine. Furthermore, this strain induced an increase in IgG antibodies against the pneumococcal insertion Spr1875. Although the A/H1N1pdm09 variant was more effective than the chimeric H1-Spr virus in preventing weight loss in mice infected with mouse-adapted influenza A/California/07/09 (H1N1)pdm09 (H1N1)pdm09 virus, the titers of the challenge virus in the lungs of mice from both vaccine groups were significantly reduced compared with unvaccinated animals.
CONCLUSIONS: The results demonstrate the ability of the chimeric recombinant H1-Spr strain to stimulate protective immunity against influenza virus.
Full Text
##article.viewOnOriginalSite##About the authors
Yulia A. Desheva
Institute of Experimental Medicine; Saint Petersburg State University
Email: desheva@mail.ru
ORCID iD: 0000-0001-9794-3520
SPIN-code: 4881-3786
MD, Dr. Sci. (Medicine), Professor of the Department of Fundamental Problems in Medicine and Medical Technologies; Leading Research Associate of the Department of Virology
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022; Saint PetersburgAndrey R. Rekstin
Institute of Experimental Medicine
Email: arekstin@yandex.ru
ORCID iD: 0000-0003-2156-1635
SPIN-code: 5359-1516
Cand. Sci. (Biology), Leading Research Associate of the Department of Virology
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Irina V. Mayorova
Institute of Experimental Medicine
Email: mayorovairina0248@gmail.com
ORCID iD: 0009-0009-5130-5000
Research Technician of the Department of Virology
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Nina V. Kopylova
Institute of Experimental Medicine
Email: KNINA5485@gmail.com
ORCID iD: 0009-0004-1963-0333
Research Technician of the Department of Virology
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Olga S. Kopteva
Institute of Experimental Medicine; Saint Petersburg State University
Email: olga.s.kopteva@yandex.ru
ORCID iD: 0000-0002-2645-3433
SPIN-code: 7630-3067
Research Associate at the world-class scientific center “Center for Personalized Medicine”, Postgraduate student
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022; Saint PetersburgDaria S. Petrachkova
Institute of Experimental Medicine
Author for correspondence.
Email: ya.dashook@ya.ru
ORCID iD: 0009-0004-0045-4886
SPIN-code: 8464-2810
Research Technician of the Department of Virology
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Polina A. Kudar
Institute of Experimental Medicine
Email: polina6226@mail.ru
ORCID iD: 0000-0002-3342-5828
SPIN-code: 9211-0537
Junior Research Associate at the world-class scientific center “Center for Personalized Medicine”
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Tatyana S. Kotomina
Institute of Experimental Medicine
Email: tstretiak@gmail.com
ORCID iD: 0000-0001-9999-089X
SPIN-code: 7613-9715
Research Associate at the Laboratory of Immunology and Prevention of Viral Infections of the A.A. Smorodintsev Virology Department
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Anastasia S. Matushkina
Institute of Experimental Medicine
Email: anastasiia.evsina@gmail.com
ORCID iD: 0000-0002-9045-0683
SPIN-code: 5437-8402
Research Associate at the A.A. Smorodintsev Virology Department
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Galina F. Leontieva
Institute of Experimental Medicine
Email: galeonte@yandex.ru
ORCID iD: 0000-0002-9876-6594
SPIN-code: 5204-9252
Cand. Sci. (Biology), Senior Research Associate at the world-class scientific center “Center for Personalized Medicine”, Senior Research Associate at the Department of Molecular Microbiology
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Tatyana A. Kramskaya
Institute of Experimental Medicine
Email: Tatyana.kramskaya@gmail.com
ORCID iD: 0000-0002-9408-6647
SPIN-code: 4529-3260
Cand. Sci. (Biology), Senior Research Associate in the Department of Molecular Microbiology
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022Irina N. Isakova-Sivak
Institute of Experimental Medicine
Email: isakova.sivak@iemspb.ru
ORCID iD: 0000-0002-2801-1508
SPIN-code: 3469-3600
Dr. Sci. (Biology), Head of the Laboratory of Immunology and Prevention of Viral Infections of the A.A. Smorodintsev Virology Department
Russian Federation, 12 Academician Pavlov St., Saint Petersburg, 197022References
- Bello S, Mincholé E, Fandos S, et al. Inflammatory response in mixed viral-bacterial community-acquired pneumonia. BMC Pulm Med. 2014;14:123. doi: 10.1186/1471-2466-14-123
- Chalmers JD, Campling J, Dicker A, et al. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med. 2016;16(1):77. doi: 10.1186/s12890-016-0242-0
- Suvorov A, Dukhovlinov I, Leontieva G, et al. Chimeric protein PSPF, a potential vaccine for prevention Streptococcus . Vaccines and Vaccination . 2015;6(6):304. doi: 10.4172/2157-7560.1000304
- Peppoloni S, Colombari B, Beninati C, et al. The Spr1875 protein confers resistance to the microglia-mediated killing of Streptococcus pneumonia . Microb Pathog. 2013;59:42–47. doi: 10.1016/j.micpath.2013.04.002
- Kramskaya T, Leontieva G, Desheva Y, et al. Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice. Plos One. 2019;14(9):e0222148. doi: 10.1371/journal.pone.0222148
- Rekstin AR, Desheva JA, Kiseleva IV, Isakova-Sivak IN. Early protection against influenza by pandemic live attenuated influenza vaccines. Medical Academic Journal. 2019;19(3):37–46. doi: 10.17816/MAJ19337-46
- Isakova-Sivak I, Tretiak T, Rudenko L. Cold-adapted influenza viruses as a promising platform for viral-vector vaccines. Expert Rev Vaccines. 2016;15(10):1241–1243. doi: 10.1080/14760584.2016.1208088
- Cardaci A, Papasergi S, Midiri A, et al. Protective activity of Streptococcus pneumoniae Spr1875 protein fragments identified using a phage displayed genomic library. PLoS One . 2012;7(5):e36588. doi: 10.1371/journal.pone.0036588
- Smolonogina TA, Isakova-Sivak IN, Kotomina TS, et al. Generation of a vaccine against group B streptococcal infection on the basis of cold-adapted influenza A virus. Mol Genet Microbiol Virol. 2019;34(1):25–34. doi: 10.3103/S0891416819010087
- Okonechnikov K, Golosova O, Fursov M; UGENE team. Unipro UGENE: a unified bioinformatics toolkit. Bioinformatics . 2012;28(8):1166–1167. doi: 10.1093/bioinformatics/bts091
- Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol . 1938;27(3):493–497. doi: 10.1093/OXFORDJOURNALS.AJE.A118408
- Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37(4):937–943. doi: 10.1128/JCM.37.4.937-943.1999
- Hoffmann E, Neumann G, Kawaoka Y, et al. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci. 2000;97(11):6108–6113. doi: 10.1073/pnas.100133697
- Desheva YA, Leontieva GF, Kramskaya TA, et al. Prevention of influenza A (H7N9) and bacterial infections in mice using intranasal immunization with live influenza vaccine and the group B streptococcus recombinant polypeptides. Virology (Auckl). 2017;8:1178122X17710949. doi: 10.1177/1178122X17710949
- Gerlach T, Elbahesh H, Saletti G, Rimmelzwaan GF. Recombinant influenza A viruses as vaccine vectors. Expert Rev Vaccines. 2019;18(4):379–392. doi: 10.1080/14760584.2019.1582338
- Kiseleva I, Dubrovina I, Fedorova E, et al. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses. Vaccine . 2015;33(49):7008–7014. doi: 10.1016/j.vaccine.2015.09.050
Supplementary files
